JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 17, Issue 2 (2025)
Iran J War Public Health 2025, 17(2): 1001-1006 |
Back to browse issues page
Article Type:
Subject:
Ethics code: 33 in 23/10/2024
History
Received: 2025/05/27 | Accepted: 2025/07/8 | Published: 2025/04/21
Received: 2025/05/27 | Accepted: 2025/07/8 | Published: 2025/04/21
How to cite this article
Abbas E C, Rasheed S M H, Naser L H, Hassan E S, Bader R M. Assessment of CCL20 Serum Level as Biomarker for Psoriasis Severity and Disease Related Comorbidities. Iran J War Public Health 2025; 17 (2) :1001-1006
URL: http://ijwph.ir/article-1-1604-en.html
URL: http://ijwph.ir/article-1-1604-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
Ebtihal Chiad Abbas1, Suaad Mohammed H. Rasheed2, Liqaa Hadi Naser2, Ekhlas Sabah Hassan *3, Rasool Moussa Bader2
1- Department of Pathology and Forensic Medicine, Faculty of Medicine. University of Kufa
2- Department of Medical Microbiology, Faculty of Medicine, University of Kufa
3- Department of pharmacology and therapeutics, Faculty of Medicine, University of Kufa ,ekhlass.khazaal@uokufa.edu.iq
2- Department of Medical Microbiology, Faculty of Medicine, University of Kufa
3- Department of pharmacology and therapeutics, Faculty of Medicine, University of Kufa ,
Abstract (7 Views)
Background: Psoriasis is a long-lasting inflammatory skin disease associated with immune system dysregulation and systemic complications. Chemokine plays a crucial role in monocyte recruitment and has been linked to the development of various autoimmune conditions.. However, its relationship with psoriasis severity and associated with disease complications remains obscure.
Aim: This study aims to propose that monitoring serum CCL20 levels in patients with psoriasis may provide valuable insights into disease severity as well as its associated complications.
Methods: A cross sectional study was conducted involving psoriasis patients. Serum CCL20 levels were measured using enzyme-linked immunosorbent assay (ELISA). Psoriasis Area and Severity Index (PASI used to assess disease severity, and information on comorbidities were collected. Statistical analyses were performed to determine associations between CCL20 levels, PASI scores, and complications.
Findings: The mean serum CCL20 levels in psoriasis patients were 112.14 ng/L ± 8.72 SE, with range values from 42.89 to 293.50. The mean CCL20 level was higher in mild disease 207.96 ± 13.88 in comparison to 132.68±15.76 for the moderate and 78.31 ± 6.48 for the severe group, (p = 0.0001). The mean serum CCL20 levels was higher significantly in patients with metabolic syndrome p=0.001, while the mean serum CCL20 levels was inversely lower in psoriatic patients with psoriatic arthritis in comparison to those had not (57.63 ±8.05 versus 123.82± 9.8, p=0.003)
Conclusion: The findings reveal an unexpected inverse relationship between serum CCL20 levels and the severity of psoriasis and Serum CCL20 levels are associated significantly with metabolic syndrome among psoriatic patients.
Aim: This study aims to propose that monitoring serum CCL20 levels in patients with psoriasis may provide valuable insights into disease severity as well as its associated complications.
Methods: A cross sectional study was conducted involving psoriasis patients. Serum CCL20 levels were measured using enzyme-linked immunosorbent assay (ELISA). Psoriasis Area and Severity Index (PASI used to assess disease severity, and information on comorbidities were collected. Statistical analyses were performed to determine associations between CCL20 levels, PASI scores, and complications.
Findings: The mean serum CCL20 levels in psoriasis patients were 112.14 ng/L ± 8.72 SE, with range values from 42.89 to 293.50. The mean CCL20 level was higher in mild disease 207.96 ± 13.88 in comparison to 132.68±15.76 for the moderate and 78.31 ± 6.48 for the severe group, (p = 0.0001). The mean serum CCL20 levels was higher significantly in patients with metabolic syndrome p=0.001, while the mean serum CCL20 levels was inversely lower in psoriatic patients with psoriatic arthritis in comparison to those had not (57.63 ±8.05 versus 123.82± 9.8, p=0.003)
Conclusion: The findings reveal an unexpected inverse relationship between serum CCL20 levels and the severity of psoriasis and Serum CCL20 levels are associated significantly with metabolic syndrome among psoriatic patients.
Keywords:
Send email to the article author